Ocular Hypertension disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: OCL006 MIFTS: 52	Ocular Hypertension Categories: Eye diseases, Neuronal diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Ocular Hypertension

MalaCards integrated aliases for Ocular Hypertension:

Name: Ocular Hypertension ¹¹ ⁵³ ⁴³ ¹⁴ ¹⁶ ⁷¹ ⁷⁵ ³³

Intraocular Pressure Increase ³³

Oht - [ocular Hypertension] ³³

Oh - [ocular Hypertension] ³³

Hypertension, Ocular ³⁸

Classifications:

MalaCards categories:
Anatomical: Eye diseases Neuronal diseases

See all MalaCards categories (disease lists)

ICD11: ³³

Diseases of the visual system

Glaucoma or glaucoma suspect

Glaucoma

Primary open-angle glaucoma

Ocular hypertension

External Ids:

Disease Ontology ¹¹ DOID:9282

ICD9CM ³⁴ 365.04

MeSH ⁴³ D009798

NCIt ⁴⁹ C3285

SNOMED-CT ⁶⁸ 267721003

EFO ¹⁶ EFO_1001069

ICD11 ³³ 535283437

UMLS ⁷¹ C0028840

Sources

Summaries for Ocular Hypertension

Disease Ontology: ¹¹ An eye disease that is characterized by elevated intraocular pressure in the absence of optic nerve damage or visual field loss.

MalaCards based summary: Ocular Hypertension, also known as intraocular pressure increase, is related to open-angle glaucoma and intraocular pressure quantitative trait locus, and has symptoms including eye manifestations An important gene associated with Ocular Hypertension is MYOC (Myocilin), and among its related pathways/superpathways are Cellular responses to stimuli and Signal Transduction. The drugs Dorzolamide and Carteolol have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and endothelial, and related phenotypes are homeostasis/metabolism and nervous system

Wikipedia: ⁷⁵ Ocular hypertension is the presence of elevated fluid pressure inside the eye (intraocular pressure),... more...

Sources

Related Diseases for Ocular Hypertension

Diseases related to Ocular Hypertension via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 292)

#	Related Disease	Score	Top Affiliating Genes
1	open-angle glaucoma	31.7	TMCO1 TGFB2 OPTN MYOC
2	intraocular pressure quantitative trait locus	31.6	TMCO1 TGFB2 PTGFR OPTN MYOC CA2
3	hypertension, essential	31.2	RHOA NR3C1 MTOR JUN HSD11B1 FOS
4	glaucoma, primary open angle	31.2	TMCO1 TGFB2 RHOA RHO PTGFR OPTN
5	glaucoma, normal tension	30.9	TMCO1 PTGFR OPTN MYOC
6	neovascular glaucoma	30.8	TGFB2 MYOC EPO
7	refractive error	30.8	TGFB2 RHO MYOC
8	primary angle-closure glaucoma	30.7	TMCO1 TGFB2 OPTN MYOC
9	retinal ischemia	30.7	RHO EPO AKT1
10	macular degeneration, age-related, 1	30.5	TGFB2 RLBP1 RHO MYOC AKT1
11	ocular pigment dispersion with or without glaucoma	30.4	TMCO1 MYOC
12	steroid-induced glaucoma	30.3	TGFB2 OPTN NR3C1 MYOC
13	acute closed-angle glaucoma	29.9	TMCO1 OPTN MYOC
14	chronic closed-angle glaucoma	29.9	TGFB2 MYOC
15	glaucoma 1, open angle, a	29.8	OPTN MYOC
16	exudative vitreoretinopathy 1	29.8	RHO EPO AKT1
17	juvenile glaucoma	29.6	TGFB2 OPTN MYOC
18	eye disease	29.3	TGFB2 RLBP1 RHOA RHO OPTN MYOC
19	retinitis pigmentosa	28.7	TGFB2 RLBP1 RHOA RHO OPTN MYOC
20	glaucoma 3, primary congenital, a	11.0
21	glaucoma, hereditary	11.0
22	glaucoma 3, primary infantile, b	10.9
23	glaucoma, hereditary adult type 1a	10.9
24	glaucoma, hereditary juvenile type 1b	10.9
25	glaucoma, primary infantile type 3a	10.9
26	glaucoma 1, open angle, f	10.9
27	optic nerve disease	10.6
28	uveitis	10.6
29	cataract	10.6
30	macular retinal edema	10.5
31	myopia	10.5
32	exfoliation syndrome	10.5
33	anterior uveitis	10.5
34	conjunctivitis	10.4
35	ocular hyperemia	10.4
36	retinal vein occlusion	10.4
37	retinal detachment	10.3
38	microvascular complications of diabetes 5	10.3
39	keratitis, hereditary	10.3
40	diabetic macular edema	10.3
41	solar retinopathy	10.2	RLBP1 RHO
42	retinal perforation	10.2	TGFB2 RLBP1 RHO
43	vitreous disease	10.2	TGFB2 RLBP1 RHO
44	macular dystrophy, dominant cystoid	10.2
45	skin atrophy	10.2	NR3C1 FKBP5 FKBP4
46	glaucoma, primary closed-angle	10.2
47	keratopathy	10.2
48	neuropathy	10.2
49	lens disease	10.2	TGFB2 RHO MYOC
50	allergic conjunctivitis	10.2

Comorbidity relations with Ocular Hypertension via Phenotypic Disease Network (PDN):

Glaucoma, Primary Open Angle

Graphical network of the top 20 diseases related to Ocular Hypertension:

Sources

Symptoms & Phenotypes for Ocular Hypertension

UMLS symptoms related to Ocular Hypertension:

eye manifestations

MGI Mouse Phenotypes related to Ocular Hypertension:

⁴⁵ (show all 14)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.41	AKT1 CA2 EPO FKBP4 FKBP5 FOS
2	nervous system	MP:0003631	10.39	AKT1 CA2 FKBP5 FOS HSD11B1 JUN
3	growth/size/body region	MP:0005378	10.3	AKT1 CA2 FKBP4 FKBP5 FOS HSD11B1
4	endocrine/exocrine gland	MP:0005379	10.21	AKT1 CA2 FKBP4 FOS HSD11B1 JUN
5	immune system	MP:0005387	10.2	AKT1 CA2 EPO FOS HSD11B1 JUN
6	normal	MP:0002873	10.19	AKT1 FKBP5 FOS JUN MTOR MYOC
7	cellular	MP:0005384	10.18	AKT1 EPO FKBP4 FOS HSD11B1 JUN
8	renal/urinary system	MP:0005367	10.1	CA2 FKBP4 FKBP5 MTOR NR3C1 RHOA
9	embryo	MP:0005380	10.1	AKT1 EPO FKBP4 FKBP5 FOS JUN
10	no phenotypic analysis	MP:0003012	10.07	JUN MLIP MTOR MYOC NR3C1 OPTN
11	respiratory system	MP:0005388	9.91	AKT1 CA2 EPO HSD11B1 JUN MTOR
12	skeleton	MP:0005390	9.85	AKT1 CA2 FOS JUN MTOR NR3C1
13	hematopoietic system	MP:0005397	9.73	AKT1 EPO FOS HSD11B1 JUN MTOR
14	mortality/aging	MP:0010768	9.5	AKT1 CA2 EPO FKBP4 FKBP5 FOS

Sources

Drugs & Therapeutics for Ocular Hypertension

Drugs for Ocular Hypertension (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 105)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Dorzolamide

Approved

Phase 4

120279-96-1

5284549

Carteolol

Approved

Phase 4

51781-06-7

2583

Sorbitol

Approved, Investigational

Phase 4

69-65-8, 50-70-4

453 6251 5780

Fluticasone

Approved, Experimental

Phase 4

90566-53-3

4659387 5311101

Dipivefrin

Approved

Phase 4

52365-63-6

3105

Mitomycin

Approved

Phase 4

50-07-7

5746

Dexamethasone acetate

Approved, Investigational, Vet_approved

Phase 4

1177-87-3

3680

Dexamethasone

Approved, Investigational, Vet_approved

Phase 4

50-02-2

3003 5743

Loteprednol etabonate

Approved, Experimental

Phase 4

82034-46-6, 129260-79-3

22227703 9865442 444025

Tobramycin

Approved, Investigational

Phase 4

32986-56-4

36294

Thymol

Approved

Phase 4

89-83-8

6989

Brinzolamide

Approved

Phase 4

138890-62-7

68844

Sympatholytics

Phase 4

Carbonic Anhydrase Inhibitors

Phase 4

Brimonidine Tartrate, Timolol Maleate Drug Combination

Phase 4

Brimonidine Tartrate

Phase 4

70359-46-5

Anti-Asthmatic Agents

Phase 4

Respiratory System Agents

Phase 4

Lubricant Eye Drops

Phase 4

Bronchodilator Agents

Phase 4

Anti-Allergic Agents

Phase 4

Xhance

Phase 4

Dermatologic Agents

Phase 4

Antibiotics, Antitubercular

Phase 4

Tobramycin, Dexamethasone Drug Combination

Phase 4

Chlorhexidine

Approved, Vet_approved, Withdrawn

Phase 3

55-56-1

2713 9552079

Betaxolol

Approved, Investigational

Phase 3

659-18-7, 63659-18-7

2369

Hydrocortisone succinate

Approved

Phase 2, Phase 3

2203-97-6

3643

Hydrocortisone acetate

Approved, Vet_approved

Phase 2, Phase 3

50-03-3

Hydrocortisone

Approved, Vet_approved

Phase 2, Phase 3

50-23-7

3640 5754

Adenosine

Approved, Investigational

Phase 3

58-61-7

60961

Apraclonidine

Approved

Phase 3

66711-21-5

2216

Benzocaine

Approved, Investigational

Phase 3

1994-09-7, 94-09-7

2337

Tannic acid

Approved

Phase 3

1401-55-4

16129878 16129778

Magnesium sulfate

Approved, Investigational, Vet_approved

Phase 3

7487-88-9

Anecortave

Investigational

Phase 2, Phase 3

10184-70-0

Chlorhexidine gluconate

Phase 3

Adrenergic beta-1 Receptor Antagonists

Phase 3

Angiogenesis Inhibitors

Phase 2, Phase 3

Hydrocortisone 17-butyrate 21-propionate

Phase 2, Phase 3

Anticonvulsants

Phase 3

Vasodilator Agents

Phase 3

Analgesics

Phase 3

Calcium, Dietary

Phase 3

calcium channel blockers

Phase 3

Tocolytic Agents

Phase 3

Calcium

Nutraceutical

Phase 3

7440-70-2

271

Acetazolamide

Approved, Vet_approved

Phase 2

59-66-5, 1424-27-7

1986

Bevacizumab

Approved, Investigational

Phase 2

216974-75-3

135329020

Nebivolol

Approved, Investigational

Phase 2

152520-56-4, 99200-09-6, 118457-14-0

71301

Interventional clinical trials:

(show top 50) (show all 597)

#	Name	Status	NCT ID	Phase	Drugs
1	An Open Label,Switch Study of the Safety and Efficacy of Combigan Ophthalmic Solution(Brimonidine 0.2% and Timolol 0.5%)With Latanoprost Compared With Latanoprost Monotherapy in Patient With Glaucoma or Ocular Hypertension.	Unknown status	NCT00442312	Phase 4	Combigan Ophthalmic Solutiom
2	Efficiency of XAL-EASE Device in Glaucoma and/or Ocular Hypertension (OHT) Patients, Treated With Xalatan or Xalacom	Unknown status	NCT01125306	Phase 4
3	IntraVitreal Triamcinolone Acetonide: Preventing Raised Eye-pressure by Tracking Elevations After Topical Steroids	Unknown status	NCT00744666	Phase 4	Prednisolone 1% topical eye drops
4	An 8 Week Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in the Treatment of Open Angle Glaucoma	Unknown status	NCT02792803	Phase 4	Xalatan;Apo-Latanoprost;Co-Latanoprost
5	IOP and Tolerability Study of Preserved Bimatoprost 0.1% or Tafluprost Unit Dose Preservative Free 15microgram/ml, in Patients With OHT or Glaucoma Suitable for Prostaglandin Therapy	Unknown status	NCT02471105	Phase 4	Preserved Bimatoprost 0.01%;Tafluprost Unit Dose Preservative Free 15microgram/ml
6	A Prospective, Randomized, Controlled Study to Assess Efficacy,Safety, and Tolerability of Selective Laser Trabeculoplasty vs. Pattern Laser Trabeculoplasty in Patients With Open-angle Glaucoma	Unknown status	NCT02231515	Phase 4
7	A Multicenter, Open-label Study of Rhopressa® (Netarsudil Ophthalmic Solution) 0.02% for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting	Completed	NCT03808688	Phase 4	Netarsudil Ophthalmic Solution 0.02%
8	Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension	Completed	NCT00822081	Phase 4	brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination;dorzolamide hcl 2%/ timolol maleate 0.5% fixed combination;brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy.;dorzolamide hcl 2%/timolol maleate 0.5% fixed combinatin as adjunctive to current prostaglandin therapy.
9	Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension	Completed	NCT00822055	Phase 4	brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination;dorzolamide hcl 2%/timolol maleate 0.5% fixed combination;brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy;dorzolamide hcl 2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy
10	Patient Satisfaction With Timolol Maleate in Sorbate, Generic Timolol Gel Forming Solution or Timolol Hemihydrate in Subjects With Open-Angle Glaucoma or Ocular Hypertension	Completed	NCT00804648	Phase 4	Timolol Maleate in Sorbate;Timolol hemihydrate;Timolol maleate gel forming solution
11	An Open, Non-randomized Pilot Study on the Effect of Preservative Free Tafluprost (Saflutan® Augentropfen) in Patients With Ocular Hypertension or Primary Open Angle Glaucoma With an Uncontrolled Intraocular Pressure of 30 mmHg and More	Completed	NCT01979913	Phase 4	Saflutan® 15 microgram/ml Augentropfen im Einzeldosisbehältnis
12	Safety and Efficacy of Brinzolamide Dosed TID With Dorzolamide Dosed TID in Reducing Intraocular Pressure in Patients With Open Angle Glaucoma or Ocular Hypertension	Completed	NCT00761995	Phase 4	Azopt;Cosopt
13	Phase IV Randomised Double-masked Clinical Trial: Assessing Morning Versus Evening Dosing of a Fixed Dose Combination of Travoprost 0.004% / Timolol Maleate 0.5% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension	Completed	NCT00759239	Phase 4	Travoprost 0.004% / Timolol maleate 0.5%
14	Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension	Completed	NCT02097719	Phase 4	bimatoprost 0.01%;travoprost 0.004%;timolol 0.5%;hypromellose 0.3%
15	A Multicenter, Open-Label Study To Evaluate The Tolerability Of Preservative Free Dorzolamide-Timolol Therapy In Patients Untreated With Open-Angle Glaucoma Or Ocular Hypertension And Dry Eye(s)	Completed	NCT00545064	Phase 4	dorzolamide hydrochloride (+) timolol maleate
16	Randomized, Investigator Masked Comparison of Istalol™ 0.5% QD (Timolol Maleate/Sorbitol Complex, ISTA Pharmaceutical) to Brimonidine Tartrate 0.1% BID as Adjunctive Therapy to Latanoprost 0.005% in Adults With Ocular Hypertension (OHT) or Open-Angle Glaucoma (OAG)	Completed	NCT00698945	Phase 4	Istalol and Optive;Alphagan
17	Safety and Efficacy of Bimatoprost Compared With Latanoprost in Patients With Glaucoma or Ocular Hypertension	Completed	NCT00541242	Phase 4	bimatoprost 0.03% eye drops;latanoprost 0.005% eye drops
18	Intraocular Pressure and Tolerability Study of Preservative Free Bimatoprost 0.03% Unit Dose (BUDPF) or Preservative Free Latanoprost 0.005% Unit Dose (LUDPF) (Monoprost®) in Patients With Ocular Hypertension or Glaucoma: A Randomized, Single Masked, 3 Month Cross-over, Investigator Led, European Multicentre Trial (SPORT)	Completed	NCT01975714	Phase 4	Preservative-free latanoprost;Preservative-free bimatoprost
19	An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension	Completed	NCT01881126	Phase 4	bimatoprost 0.01%;travatan 0.004%;timolol 0.5%;hypromellose 0.3%
20	Evaluation of the Safety of GANFORT® (Bimatoprost 0.03% Plus Timolol 0.5%) Ophthalmic Solution in Chinese Patients With Open-angle Glaucoma or Ocular Hypertension	Completed	NCT02571712	Phase 4	bimatoprost 0.03% plus timolol 0.5%
21	A Single Dose Comfort Comparison of Travatan Z in One Eye Versus Xalatan in the Opposite Eye in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension	Completed	NCT00527592	Phase 4	Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®);Latanoprost ophthalmic solution 0.005% (XALATAN®)
22	Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01% and Lumigan® 0.03% Unit Dose, in Patients With Primary Open Angle Glaucoma or Ocular Hypertension, Stabilized by Lumigan® 0.01% With Ocular Surface Intolerance	Completed	NCT02017327	Phase 4	Monoprost;Lumigan 0.01%;Lumigan 0.03% Unit Dose
23	Open Multicenter Study on the Efficacy of Xalatan at 3 Months as First-line Therapy in Naive Patients With Ocular Hypertension (OH) or Open Angle Glaucoma (OAG), Based on Initial Intraocular Pressure (IOP): 20 mmHg Less Than or Equal to IOP Less Than 24 mmHg, IOP Greater Than or Equal to 24 mmHg	Completed	NCT00647101	Phase 4	Latanoprost
24	Randomized Crossover Trial Comparing the Hypotensive Effect of Generic Travoprost With That of the Brand Name Travoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension	Completed	NCT02796560	Phase 4	Brand name travoprost;Generic travoprost
25	An Evaluation of the Fixed Combination Brimonidine Tartrate 0.2%/ Timolol Maleate 0.5% to Latanoprost 0.005% in Glaucoma or Ocular Hypertension Subjects	Completed	NCT00811564	Phase 4	fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution;latanoprost 0.005%
26	An 8 Week, Single Masked, Parallel-Group, Exploratory Study Comparing Ocular Surface Signs and Symptoms in Monotherapy Ocular Hypertension or Glaucoma Patients Randomized to Either Xalatan® or Travatan Z®	Completed	NCT00799682	Phase 4	Xalatan;Travatan Z
27	A Twelve-Week, Double Masked, Parallel Group, Study of Travoprost 0.004% Compared to Timolol 0.5% in Patients With Open-Angle Glaucoma or Ocular Hypertension	Completed	NCT00763061	Phase 4	Travoprost 0.004% Ophthalmic Solution (Travatan);Timolol 0.5% Ophthalmic Solution (Timoptic)
28	Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension Subjects	Completed	NCT00735449	Phase 4	Fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%;timolol maleate 0.5%;latanoprost 0.005%
29	A Study of Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension	Completed	NCT02061683	Phase 4	Bimatoprost 0.03%
30	A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension	Completed	NCT02020512	Phase 4	0.03% Bimatoprost
31	A Study of 0.15% Brimonidine Tartrate in Patients With Primary Open Angle Glaucoma and Ocular Hypertension	Completed	NCT02003534	Phase 4	0.15% Brimonidine Tartrate
32	A Phase IV Study of Travoprost + Brinzolamide to Treat Glaucoma or Ocular Hypertension	Completed	NCT00471380	Phase 4	travoprost 0.004% and brinzolamide 1%;fixed combination of timolol 0.5% and dorzolamide 2% plus travoprost vehicle
33	Efficacy and Safety of Timolol Maleate 0.5% Compared to Brinzolamide 1% When Added to Travoprost 0.004% in Primary Open-angle Glaucoma or Ocular Hypertension	Completed	NCT00372827	Phase 4	Brinzolamide 1% added to Travoprost 0.004%
34	A 12-Week Randomized, Evaluator-Masked, Parallel-Group, Multinational, Multi-Center Study Comparing The Efficacy And Safety Of The Fixed Combination Of Latanoprost And Timolol (Xalacom) With The Fixed Combination Of Dorzolamide And Timolol (Cosopt) In Patients With Open-Angle Glaucoma Or Ocular Hypertension.	Completed	NCT00140049	Phase 4	Xalacom;Cosopt
35	Assessing the Efficacy and Tolerability of TRAVATAN® Solution Without BAK, Containing Polyquad® Preservative (Travoprost 0.004%) Versus LUMIGAN® 0.01% Solution With BAK (Bimatoprost 0.01%) in Treatment Naïve Patients With Ocular Hypertension or Open Angle Glaucoma	Completed	NCT01664039	Phase 4	Travoprost 0.004% ophthalmic solution;Bimatoprost 0.01% ophthalmic solution
36	A Randomized, Parallel, Open-label Study to Evaluate Efficacy and Safety Effects Using Mikelan® LA Ophthalmic Solution (OS) 2% Versus Timoptol® XE Ophthalmic Solution (OS) 0.5% in Ocular Hypertension Patients	Completed	NCT00972426	Phase 4	carteolol (Mikelan), timolol (Timoptol), latanoprost (Xalatan)
37	The Effect of Inhaled Corticosteroids on Intraocular Pressure in Patients With Ocular Hypertension or Controlled Glaucoma.	Completed	NCT02338362	Phase 4	Fluticasone propionate inhaler;Saline placebo inhaler
38	An Open, Non-randomized Study on the Effect of Changing From Preserved Prostaglandin Formulations to Preservative Free Tafluprost (Saflutan® Augentropfen) in Patients With Ocular Hypertension or Primary Open Angle Glaucoma on Tear Film Thickness	Completed	NCT03204487	Phase 4	Tafluprost 15µg/ml
39	Comparison of the Efficacy of AZARGA® Versus COSOPT® in Patients With Open-Angled Glaucoma or Ocular Hypertension	Completed	NCT01111890	Phase 4	Azarga (brinzolamide 1% / timolol 0.5%);Cosopt (dorzolamide 2% / timolol 0.5%)
40	The Efficacy and Safety of Brinzolamide 1%/Timolol 0.5% Fixed Combination Versus Dorzolamide 1%/Timolol 0.5% in Patients With Open-Angle Glaucoma and Ocular Hypertension	Completed	NCT02325518	Phase 4	Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension;Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution;Subject's habitual PGA monotherapy
41	Efficacy Of The Bimatoprost/Timolol Fixed Combination In Patients Treated With Bimatoprost for Primary Open Angle Glaucoma, Exfoliation Glaucoma or Ocular Hypertension.	Completed	NCT00941096	Phase 4	Bimatoprost and Bimatoprost/Timolol fixed combination.
42	A Randomized Post-Marketing Efficacy And Safety Study Of Xalatan Compared With "Usual Care" Over 36 Months In Patients With Primary Open-Angle Glaucoma, Exfoliative Glaucoma Or Ocular Hypertension	Completed	NCT00140062	Phase 4	latanoprost 0.005% (Xalatan)
43	A Double-Masked, Placebo-Controlled, Paired Comparison Study of the Mechanism of Action of TRAVATAN 0.004% in Subjects With Glaucoma or Ocular Hypertension	Completed	NCT00061503	Phase 4	Travoprost
44	The 24 Control of IOP in Ocular Hypertension: a Cross-over Study on Inflow Versus Outflow Drugs.	Completed	NCT01655758	Phase 4	0.5% timolol;timolol-dorzolamide fixed combination;Latanoprost;Travoprost;Bimatoprost
45	A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH)	Completed	NCT01594970	Phase 4	Bimatoprost 0.01%
46	A Multicenter Evaluation of Methods to Reduce Hyperemia Associated With Bimatoprost Therapy for Glaucoma or Ocular Hypertension	Completed	NCT00348062	Phase 4	Bimatoprost
47	Comparison of Bimatoprost 0.03% Monotherapy vs. Dual Therapy With Travoprost 0.004% and Timolol 0.5% in Patients With Glaucoma and Ocular Hypertension	Completed	NCT00348023	Phase 4	Bimatoprost 0.03%, Travoprost 0.004%, Timolol 0.5%
48	24-Hour Intraocular Pressure (IOP) And Blood Pressure Control In Glaucoma And Ocular Hypertension Patients	Completed	NCT00330577	Phase 4	timolol maleate 0.5%;latanoprost/timolol fixed combination;placebo (artificial tears)
49	A Multiple-Dose Study of the IOP-Lowering Efficacy of Azopt 1.0% Compared to Timolol 0.5% When Added to a PGA as Adjunctive Therapy Over a 24 Hour Period in Patients With Glaucoma or Ocular Hypertension	Completed	NCT00300079	Phase 4	brinzolamide 1.0%
50	Health-Related Quality of Life in Two Pathways for Newly Diagnosed Open Angle Glaucoma and Ocular Hypertension: an Unmasked, Multi-centre, Randomised Controlled Trial of Initial Selective Laser Trabeculoplasty Versus Medical Therapy	Completed	NCT03395535	Phase 4	Primary Medical Treatment Pathway

Search NIH Clinical Center for Ocular Hypertension

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

apraclonidine

Apraclonidine hydrochloride

Mannitol

Mannitol hexanitrate

MANNITOL PWDR

Urea

UREA POWDER

Cochrane evidence based reviews: ocular hypertension

Sources

Genetic Tests for Ocular Hypertension

Sources

Anatomical Context for Ocular Hypertension

Organs/tissues related to Ocular Hypertension:

MalaCards : Eye, Retina, Endothelial, Thyroid, Bone Marrow, Skin, Brain

Sources

Publications for Ocular Hypertension

Articles related to Ocular Hypertension:

(show top 50) (show all 5888)

#	Title	Authors	PMID	Year
1	Assessment of SNPs associated with the human glucocorticoid receptor in primary open-angle glaucoma and steroid responders. ⁵³ ⁶²	Fingert JH...Clark AF	20376328	2010
2	Overexpression of myocilin in the Drosophila eye activates the unfolded protein response: implications for glaucoma. ⁵³ ⁶²	Carbone MA...Anholt RR	19148291	2009
3	[Expression of glucocorticoid receptors alpha and beta in mononuclear cells of peripheral blood in patients with glucocorticoid-induced ocular hypertension]. ⁵³ ⁶²	Li GG...Bi JJ	19484926	2009
4	Aqueous humor myocilin protein levels in normal, genetic carriers, and glaucoma Beagles. ⁵³ ⁶²	Mackay EO...Gelatt KN	18435660	2008
5	Role of MYOC and OPTN sequence variations in Spanish patients with primary open-angle glaucoma. ⁵³ ⁶²	Lopez-Martinez F...Escribano J	17615537	2007
6	The variant N363S of glucocorticoid receptor in steroid-induced ocular hypertension in Hungarian patients treated with photorefractive keratectomy. ⁵³ ⁶²	Szabo V...Nagy ZZ	17563720	2007
7	Myocilin-associated exosomes in human ocular samples. ⁵³ ⁶²	Perkumas KM...Stamer WD	17094967	2007
8	Coiled-coil targeting of myocilin to intracellular membranes. ⁵³ ⁶²	Stamer WD...McKay BS	16973161	2006
9	Novel myocilin mutation in a Chinese family with juvenile-onset open-angle glaucoma. ⁵³ ⁶²	Fan BJ...Pang CP	16401791	2006
10	Characterization of rabbit myocilin: Implications for human myocilin glycosylation and signal peptide usage. ⁵³ ⁶²	Shepard AR...Clark AF	12697062	2003
11	Myocilin glaucoma. ⁵³ ⁶²	Fingert JH...Alward WL	12504739	2002
12	Rapid mutation detection by the transgenomic wave analyser DHPLC identifies MYOC mutations in patients with ocular hypertension and/or open angle glaucoma. ⁵³ ⁶²	Cobb CJ...McLean WH	11815346	2002
13	Glucocorticoid induction of the glaucoma gene MYOC in human and monkey trabecular meshwork cells and tissues. ⁵³ ⁶²	Clark AF...Stone EM	11431441	2001
14	Evaluation of the myocilin (MYOC) glaucoma gene in monkey and human steroid-induced ocular hypertension. ⁵³ ⁶²	Fingert JH...Stone EM	11133859	2001
15	Characterization and differential expression of a human gene family of olfactomedin-related proteins. ⁵³ ⁶²	Kulkarni NH...Anholt RR	11006633	2000
16	Neuroaxonal and cellular damage/protection by prostanoid receptor ligands, fatty acid derivatives and associated enzyme inhibitors. ⁶²	Sharif NA	35799502	2023
17	Clinical patterns and risk factors in scleritis: a multicentric study in Colombia. ⁶²	de-la-Torre A...Rojas-Carabali W	35796822	2022
18	The Effect of Latanoprost on Choroidal Vascularity Index in Glaucoma and Ocular Hypertension. ⁶²	Cakir I...Altan C	35980849	2022
19	Do motivational cards really benefit sibling screening of primary open-angle glaucoma probands? ⁶²	Gurnani B...Kaur K	36453305	2022
20	Effect of prostaglandin analogues on the biomechanical corneal properties in patients with open-angle glaucoma and ocular hypertension measured with dynamic scheimpflug analyzer. ⁶²	Martinez-Sanchez MI...Teus MA	35841397	2022
21	Topical prostaglandin analogue use and cystoid macular oedema following uneventful cataract surgery: a randomised control trial. ⁶²	Niyadurupola N...Broadway DC	34045222	2022
22	Epidemiology of ectopia lentis and outcomes after surgery in a Danish population. ⁶²	Rasul A...Kessel L	36449672	2022
23	Real world outcomes of sutureless and glueless sclerally fixated intraocular lens implantation. ⁶²	Gajula S...Narendran V	34980895	2022
24	Ocular hypertension in patients with active thyroid-associated orbitopathy: a predictor of disease severity, particularly of extraocular muscle enlargement. ⁶²	Karhanova M...Sin M	35834036	2022
25	Decreased outflow facility and Schlemm's canal defects in a mouse model of glaucoma. ⁶²	Mavlyutov TA...McDowell CM	36152913	2022
26	Microglia depletion exacerbates retinal ganglion cell loss in a mouse model of glaucoma. ⁶²	Tan Z...Jakobs TC	36206859	2022
27	The Effect of Prostaglandin Analogues on Central Corneal Thickness of Patients with Glaucoma or Ocular Hypertension: a systematic review. ⁶²	Lu Y...Cao Y	36455536	2022
28	Increased Risk of Ocular Hypertension in Patients With Cushing's Disease. ⁶²	Ma Y...Zhao Y	35980841	2022
29	Optic Disc Drusen in Patients With Ocular Hypertension: A Case Series and Review of the Literature. ⁶²	Kohli D...Roddy GW	35916300	2022
30	Efficacy and effectiveness of anti-VEGF or steroids monotherapy versus combination treatment for macular edema secondary to retinal vein occlusion: a systematic review and meta-analysis. ⁶²	Zhang W...Sang A	36474156	2022
31	Impairments of retinal hemodynamics and oxygen metrics in ocular hypertension-induced ischemia-reperfusion. ⁶²	Rahimi M...Shahidi M	36252653	2022
32	Letter to the Editor: Association of Metabolic Syndrome With Glaucoma and Ocular Hypertension in a Midwest United States Population. ⁶²	Arora C...Gogoi D	36223295	2022
33	Response to Letter to the Editor: Association of Metabolic Syndrome With Glaucoma and Ocular Hypertension in a Midwest United States Population. ⁶²	Roddy GW	36223292	2022
34	Astrocyte polarization in glaucoma: a new opportunity. ⁶²	Liu YX...Guo WY	35662185	2022
35	Sustained release of brimonidine from [email protected]@TPU implant for treatment of glaucoma. ⁶²	Zhao Y...Sun J	35174743	2022
36	Protocol for laser-induced chronic ocular hypertension and intracameral injection in nonhuman primates. ⁶²	Sun D...Lan Y	36340883	2022
37	Machine-Identified Patterns of Visual Field Loss and an Association with Rapid Progression in the Ocular Hypertension Treatment Study. ⁶²	Yousefi S...Johnson CA	35817199	2022
38	Nobiletin protects retinal ganglion cells in models of ocular hypertension in vivo and hypoxia in vitro. ⁶²	Wang DD...Wu JH	35804043	2022
39	A Novel and Reversible Experimental Primate Ocular Hypertension Model: Blocking Schlemm's Canal. ⁶²	Jiang J...Liang YB	36380650	2022
40	Sphingomyelinases in retinas and optic nerve heads: Effects of ocular hypertension and ischemia. ⁶²	Fan J...Crosson CE	36122624	2022
41	Effect of topical nitric oxide donors 0.03% nitroglycerin and 0.1% hydralazine on intraocular pressure in healthy canine eyes. ⁶²	Wilcox PA...Allbaugh RA	36137290	2022
42	Estimation of the intraoperative blood loss in dogs undergoing enucleation. ⁶²	Lenihan E...Walsh K	36322454	2022
43	Sympathetic activation leads to Schlemm's canal expansion via increasing vasoactive intestinal polypeptide secretion from trabecular meshwork. ⁶²	Xu D...Zhao Y	36049555	2022
44	Stress induced aging in mouse eye. ⁶²	Xu Q...Skowronska-Krawczyk D	36397653	2022
45	Changes in Intraocular Pressure following Narcosis With Medetomidine, Midazolam, and Fentanyl in Association With Initial Intraocular Pressure in Mice. ⁶²	Binter M...Tode J	35943353	2022
46	Safety of Fixed-Combination Bimatoprost 0.03%/Timolol 0.5% Ophthalmic Solution at 6 Months in Chinese Patients with Open-Angle Glaucoma or Ocular Hypertension. ⁶²	Sun X...Goodkin ML	36370233	2022
47	Potential for Collider Bias in Studies Examining the Association of Central Corneal Thickness With Glaucoma. ⁶²	Khawaja AP...Jansonius NM	36322067	2022
48	Endocyclophotocoagulation by pars plana approach in the management of refractory glaucoma with prior phacoemulsification and Ahmed gonioimplantation in a dog. ⁶²	Kaminsky M...Konrade K	36321590	2022
49	Suprachoroidal injection of polyzwitterion hydrogel for treating glaucoma. ⁶²	Hao H...Liu W	36279749	2022
50	Use of selective laser trabeculoplasty as an alternative in patients who developed ocular hypertension after intravitreal dexamethasone implants: a series of 35 eyes. ⁶²	Billant J...Dot C	35665853	2022

Sources

Genes for Ocular Hypertension

Genes related to Ocular Hypertension (0 elite genes):

(show all 32)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	MYOC	Myocilin	Protein Coding	27.57	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11133859 16973161 11431441 (more) 11815346 19148291 18435660 17094967 11006633 16401791 12504739 12697062 17615537
2	EPO	Erythropoietin	Protein Coding	21.49	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Summaries (show sections)
3	NR3C1	Nuclear Receptor Subfamily 3 Group C Member 1	Protein Coding	17.94	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	19484926 20376328 17563720
4	PTGFR	Prostaglandin F Receptor	Protein Coding	15.22	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
5	TGFB2	Transforming Growth Factor Beta 2	Protein Coding	14.63	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
6	TMCO1	Transmembrane And Coiled-Coil Domains 1	Protein Coding	13.41	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
7	OPTN	Optineurin	Protein Coding	13.31	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	17615537 16401791
8	CA2	Carbonic Anhydrase 2	Protein Coding	13.2	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
9	RHOA	Ras Homolog Family Member A	Protein Coding	13.01	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
10	RHO	Rhodopsin	Protein Coding	12.75	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
11	AKT1	AKT Serine/Threonine Kinase 1	Protein Coding	12.7	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
12	JUN	Jun Proto-Oncogene, AP-1 Transcription Factor Subunit	Protein Coding	12.5	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
13	RLBP1	Retinaldehyde Binding Protein 1	Protein Coding	12.29	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
14	FKBP5	FKBP Prolyl Isomerase 5	Protein Coding	11.9	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
15	MLIP	Muscular LMNA Interacting Protein	Protein Coding	11.83	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
16	FOS	Fos Proto-Oncogene, AP-1 Transcription Factor Subunit	Protein Coding	11.73	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
17	FKBP4	FKBP Prolyl Isomerase 4	Protein Coding	11.68	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
18	MTOR	Mechanistic Target Of Rapamycin Kinase	Protein Coding	11.45	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
19	HSD11B1	Hydroxysteroid 11-Beta Dehydrogenase 1	Protein Coding	11.42	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
20	SRSF3	Serine And Arginine Rich Splicing Factor 3	Protein Coding	11.21	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
21	CXCL12	C-X-C Motif Chemokine Ligand 12	Protein Coding	11	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
22	PTEN	Phosphatase And Tensin Homolog	Protein Coding	10.99	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
23	NR3C2	Nuclear Receptor Subfamily 3 Group C Member 2	Protein Coding	10.76	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
24	TXN	Thioredoxin	Protein Coding	10.71	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
25	SERPINA6	Serpin Family A Member 6	Protein Coding	10.52	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
26	EPOR	Erythropoietin Receptor	Protein Coding	10.42	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
27	TXN2	Thioredoxin 2	Protein Coding	10.36	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
28	CXCR3	C-X-C Motif Chemokine Receptor 3	Protein Coding	10.17	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
29	CRYAA	Crystallin Alpha A	Protein Coding	9.34	DISEASES inferred ¹⁴ ¹⁴
30	POU4F1	POU Class 4 Homeobox 1	Protein Coding	8.06	DISEASES inferred ¹⁴
31	HCG22	HLA Complex Group 22 (Gene/Pseudogene)	Protein Coding	7.72	GeneCards inferred via : Publications (show sections)
32	DRD3	Dopamine Receptor D3	Protein Coding	7.56	GeneCards inferred via : Publications (show sections)

Sources

Variations for Ocular Hypertension

Sources

Expression for Ocular Hypertension

Search GEO for disease gene expression data for Ocular Hypertension.

Sources

Pathways for Ocular Hypertension

Pathways related to Ocular Hypertension according to GeneCards Suite gene sharing:

(show top 50) (show all 71)

#	Super pathways	Score	Top Affiliating Genes
1	Cellular responses to stimuli ⁶⁶ Show member pathways Cellular responses to stress ⁶⁶	13.46	NR3C1 MTOR JUN FOS FKBP5 FKBP4
2	Signal Transduction ⁶⁶	13.38	TGFB2 RHOA RHO PTGFR OPTN NR3C1
3	p70S6K Signaling ⁶⁴ Show member pathways mTOR Pathway ⁶⁴ Renin-Angiotensin Pathway ⁶⁴	13.04	TGFB2 RHOA MTOR JUN FOS AKT1
4	Sertoli-Sertoli Cell Junction Dynamics ⁶⁴ Show member pathways Epithelial Tight Junctions ⁶⁴ Germ Cell-Sertoli Cell Junction Dynamics ⁶⁴	12.92	TGFB2 RHOA JUN FOS AKT1
5	Beta-Adrenergic Signaling ⁶⁴ Show member pathways CDK5 Pathway ⁶⁴ Erythropoietin Pathway ⁶⁴ Insulin Pathway ⁷⁰ Insulin Receptor Pathway ⁶⁴	12.89	MTOR JUN FOS EPO AKT1
6	NFAT and Cardiac Hypertrophy ⁶⁴ Show member pathways IGF1R Signaling ⁶⁴ Signaling Involved in Cardiac Hypertrophy ⁶⁴	12.87	TGFB2 RHOA MTOR JUN AKT1
7	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.66	TGFB2 RHOA MTOR JUN FOS AKT1
8	Angiopoietin-like protein 8 regulatory pathway ⁷⁴ Show member pathways Insulin signaling ⁷⁴ Liver X receptor pathway ⁷⁴	12.52	MTOR JUN FOS AKT1
9	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	12.46	MTOR JUN FOS AKT1
10	Development EGFR signaling pathway ²² Show member pathways Development ERBB-family signaling ²² EGF Pathway ⁶⁴ EGFR Signaling Pathway ⁶⁷ ErbB receptor signaling network ⁶¹	12.46	RHOA MTOR JUN FOS AKT1
11	VEGF Pathway (Qiagen) ⁶⁴ Show member pathways CCKBR-Gastrin Stimulated Signaling ⁶⁴ Development VEGF-family signaling ²² Neurophilin interactions with VEGF and VEGFR ⁶⁶ VEGF and VEGFR signaling network ⁶¹ VEGF Family Ligands and Receptor Interactions ⁶⁴	12.44	RHOA JUN FOS AKT1
12	WNT Signaling ⁶⁴	12.43	RHOA JUN FOS AKT1
13	Development Dopamine D2 receptor transactivation of EGFR ²² Show member pathways Chemotaxis CXCR4 signaling pathway ²² Development Alpha-2 adrenergic receptor activation of ERK ²² Extra-nuclear estrogen signaling ⁶⁶	12.42	RHOA JUN FOS AKT1
14	MAPK signaling pathway ⁷⁴	12.41	TGFB2 JUN FOS AKT1
15	Development VEGF signaling via VEGFR2 - generic cascades ²² Show member pathways Development VEGF signaling and activation ²² VEGF - VEGF R2 Signaling Pathways ⁶⁵	12.4	RHOA JUN FOS AKT1
16	G-protein signaling RAC1 in cellular process ²² Show member pathways CDC42 signaling events ⁶¹ Cytoskeleton remodeling CDC42 in cellular processes ²² RAC1 signaling pathway ⁶¹	12.39	TGFB2 RHOA MTOR JUN FOS
17	Cell cycle Regulation of G1/S transition (part 1) ²² Show member pathways Cell cycle ESR1 regulation of G1/S transition ²² Cell cycle Role of SCF complex in cell cycle regulation ²² Immune response MIF-JAB1 signaling ²² Mitotic Roles of Polo Like Kinases ⁶⁴	12.37	TGFB2 NR3C1 JUN FOS
18	B Cell Receptor Signaling Pathway ⁶⁷ Show member pathways T Cell Receptor Signaling Pathway ⁶⁷	12.31	MTOR JUN FOS AKT1
19	Integrin-mediated cell adhesion ⁷⁴ Show member pathways HGF Pathway ⁶⁴	12.25	RHO JUN FOS AKT1
20	PDGFR-beta signaling pathway ⁶¹ Show member pathways ErbB1 downstream signaling ⁶¹	12.22	AKT1 FOS JUN MTOR RHOA
21	T-cell activation SARS-CoV-2 ⁷⁴ Show member pathways T-cell antigen receptor (TCR) pathway during Staphylococcus aureus infection ⁷⁴	12.13	MTOR JUN FOS AKT1
22	Integrated breast cancer pathway ⁷⁴	12.13	RHO MTOR JUN AKT1
23	Translation Translation regulation by Alpha-1 adrenergic receptors ²² Show member pathways Development Activation of ERK by Alpha-1 adrenergic receptors ²²	12.01	RHOA MTOR JUN FOS
24	IL12-mediated signaling events ⁶¹ Show member pathways Immune response IL-12-induced IFN-gamma production ²²	11.97	MTOR JUN FOS
25	Gastrin signaling pathway ⁷⁴	11.96	AKT1 FOS JUN RHOA
26	Corticotropin-releasing hormone signaling pathway ⁷⁴	11.87	AKT1 FOS RHOA
27	IL2 signaling events mediated by STAT5 ⁶¹ Show member pathways IL2 signaling events mediated by PI3K ⁶¹ IL2-mediated signaling events ⁶¹ Interleukin-2 signaling ⁶⁶	11.85	AKT1 FOS JUN MTOR RHOA
28	Clear cell renal cell carcinoma pathways ⁷⁴	11.83	TGFB2 MTOR AKT1
29	MECP2 and associated Rett syndrome ⁷⁴	11.75	AKT1 FKBP5 MTOR
30	Regulation of nuclear SMAD2/3 signaling ⁶¹	11.73	NR3C1 JUN FOS AKT1
31	Th17 cell differentiation pathway ⁷⁴	11.72	MTOR JUN FOS
32	AP-1 transcription factor network ⁶¹	11.72	NR3C1 JUN FOS
33	Neural crest cell migration in cancer ⁷⁴ Show member pathways Cell migration and invasion through p75NTR ⁷⁴ Neural crest cell migration during development ⁷⁴	11.69	RHOA JUN AKT1
34	Physico-chemical features and toxicity-associated pathways ⁷⁴	11.68	RHOA JUN AKT1
35	BCR signaling pathway ⁶¹	11.68	JUN FOS AKT1
36	Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) ⁶¹	11.68	RHOA MTOR JUN AKT1
37	Photodynamic therapy-induced NF-kB survival signaling ⁷⁴ Show member pathways Immune response MIF-mediated glucocorticoid regulation ²²	11.66	NR3C1 JUN FOS
38	Serotonin HTR1 group and FOS pathway ⁷⁴ Show member pathways Serotonin receptor 2 and ELK-SRF/GATA4 signaling ⁷⁴ Serotonin receptor 4/6/7 and NR3C signaling ⁷⁴	11.65	FOS NR3C1 RHOA
39	Regulation of Telomerase ⁶¹	11.64	MTOR JUN FOS AKT1
40	ATF-2 transcription factor network ⁶¹	11.61	TGFB2 JUN FOS
41	HIF-1-alpha transcription factor network ⁶¹	11.61	JUN FOS EPO AKT1
42	IL-2 Gene Expression in Activated and Quiescent T-Cells ⁶⁴ Show member pathways TOB in T-Cell Signaling ⁶⁴	11.6	TGFB2 JUN FOS AKT1
43	Proteolysis Putative SUMO-1 pathway ²² Show member pathways DNA damage Role of SUMO in p53 regulation ²²	11.58	NR3C1 JUN AKT1
44	FGF signaling pathway ⁶¹	11.58	JUN FOS AKT1
45	Netrin-UNC5B signaling pathway ⁷⁴	11.56	RHOA JUN AKT1
46	IL6-mediated signaling events ⁶¹	11.48	AKT1 FOS JUN
47	LPA receptor mediated events ⁶¹	11.43	RHOA JUN FOS AKT1
48	E-cadherin signaling in the nascent adherens junction ⁶¹ Show member pathways AlphaE beta7 integrin cell surface interactions ⁶¹	11.4	RHOA CA2 AKT1
49	Crizotinib Pathway, Pharmacokinetics/Pharmacodynamics ⁶⁰	11.39	MTOR JUN AKT1
50	Transcription_Role of VDR in regulation of genes involved in osteoporosis ²²	11.39	NR3C1 JUN FOS CA2

Sources

GO Terms for Ocular Hypertension

Cellular components related to Ocular Hypertension according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	transcription factor AP-1 complex	GO:0035976	8.92	FOS JUN

Biological processes related to Ocular Hypertension according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of stress fiber assembly	GO:0051496	9.88	RHOA MYOC MTOR
2	positive regulation of neuron apoptotic process	GO:0043525	9.85	TGFB2 RHOA NR3C1
3	cellular response to reactive oxygen species	GO:0034614	9.73	JUN FOS AKT1
4	cellular response to cadmium ion	GO:0071276	9.63	AKT1 FOS JUN
5	heart valve morphogenesis	GO:0003179	9.62	TGFB2 MTOR
6	positive regulation of cell growth	GO:0030307	9.56	TGFB2 RHOA MTOR AKT1
7	positive regulation of miRNA transcription	GO:1902895	9.23	TGFB2 NR3C1 JUN FOS